CLINICAL TRIAL / NCT04295863

Inclusion Criteria: - Patients with locally advandced or metastatic cancer whose physician has determined they are candidates for treatment with nivolumab or pembrolizumab - 18 years old or older - Measurable disease per RECIST criteria Exclusion Criteria: - Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy. - Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal antibody in combination with either nivolumab or pembrolizumab. - Ipilimumab and nivolumab combination are not eligible for this trial. - (Note: Patients whose planned treatment is the combination of anti-PD-1 and tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of traditional cytotoxic chemotherapy and anti-PD-1 are eligible)